Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages
Journal of Thrombosis and Haemostasis2020Vol. 18(7), pp. 1637–1647
Citations Over TimeTop 10% of 2020 papers
Megan E. Barra, Alvin S. Das, Bryan D. Hayes, Eric S. Rosenthal, Rachel Rosovsky, Lanting Fuh, Aman B. Patel, Joshua N. Goldstein, Russel J. Roberts
Related Papers
- → Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator(2018)42 cited
- → Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery(2015)5 cited
- A new strategy for uncontrollable bleeding after treatment with rivaroxaban or apixaban.(2019)
- → The effects of direct oral anticoagulants apixaban and rivaroxaban on haemostasis tests(2015)1 cited
- → ▼ Apixaban and ▼ rivaroxaban for stroke prevention in AF(2014)1 cited